Solventum
SOLV
$75.10
+1.32%
Solventum Corporation is a healthcare company that develops, manufactures, and commercializes solutions leveraging material science, data science, and digital capabilities to address customer and patient needs across its MedSurg, Dental Solutions, and Health Information Systems segments. The company is a recent spin-off, establishing its identity as a standalone entity in the competitive medical supplies and software landscape, with its MedSurg segment being the primary revenue driver. The current investor narrative centers on the company's performance as an independent public entity, with attention focused on its ability to execute its growth strategy, manage its capital structure post-spin-off, and demonstrate sustainable profitability amidst a challenging market environment for healthcare supplies.…
SOLV
Solventum
$75.10
Investment Opinion: Should I buy SOLV Today?
Rating: Hold. The core thesis is that SOLV presents a classic value trap—deeply cheap on earnings multiples but with fundamental business momentum that is undeniably negative, making a near-term catalyst for re-rating elusive.
Supporting evidence includes a trailing P/E of 8.87x and forward P/E of 9.55x, which are at a clear discount to the healthcare sector, and a Price-to-Sales ratio of 1.66x. However, this valuation is counteracted by a -3.71% YoY revenue decline in the latest quarter and negative TTM free cash flow of -$10M. The stock also trades 24.5% below its 52-week high, reflecting persistent negative sentiment. Analyst consensus is bullish but based on a wide EPS estimate range ($7.26 to $8.00), indicating high uncertainty.
The two biggest risks are continued revenue contraction and a breakdown below the $62.38 technical support level. This Hold rating would upgrade to a Buy if the company reports two consecutive quarters of positive revenue growth and generates positive quarterly free cash flow, demonstrating operational turnaround. It would downgrade to a Sell if revenue decline accelerates beyond -5% YoY or if the stock decisively breaks below $62.38 on high volume. The valuation verdict is that the stock is fairly valued to slightly undervalued relative to its depressed fundamentals, but not sufficiently cheap to offset the clear operational headwinds.
Sign up to view all
SOLV 12-Month Price Forecast
The investment case for SOLV is bifurcated between compelling value and troubling fundamentals. The stock is undeniably cheap, but the market is correctly skeptical of its ability to grow. The neutral stance reflects this stalemate; the value is real, but a catalyst is needed. The primary factor to monitor is the revenue trajectory. An upgrade to a bullish stance would require clear evidence of sustainable top-line growth for at least two quarters. A downgrade to bearish would be triggered by an acceleration of the revenue decline or a breakdown of key support at $62.38, which would invalidate the value floor thesis.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Solventum's 12-month outlook, with a consensus price target around $97.63 and implied upside of +30.0% versus the current price.
Average Target
$97.63
4 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
4
covering this stock
Price Range
$60 - $98
Analyst target range
Analyst coverage for Solventum is limited, with only 3 analysts providing estimates, which is typical for a recently spun-off mid-cap company and can lead to higher volatility and less efficient price discovery. The consensus leans bullish among the firms that do cover it, with recent institutional ratings including 'Overweight' from Keybanc, 'Buy' from BTIG and Stifel, and 'Outperform' from Mizhuo, though Wells Fargo maintains an 'Equal Weight' rating. The target price range implied by earnings estimates is wide, with a low EPS estimate of $7.26 and a high of $8.00, reflecting significant uncertainty about the company's future earnings power and the assumptions needed to achieve its standalone potential post-spin-off.
Bulls vs Bears: SOLV Investment Factors
The evidence currently tilts bearish, driven by the undeniable headwinds of declining revenue, negative free cash flow, and a powerful technical downtrend. The bull case rests almost entirely on a deep-value valuation argument and analyst optimism, which have so far failed to stem the selling pressure. The single most important tension in the investment debate is whether SOLV's discounted valuation (P/E of 8.87x) is a compelling trap for value investors or a justified reflection of a business in secular decline with no clear path to reigniting growth. The resolution of this tension hinges entirely on the company demonstrating a sustainable reversal in its top-line trajectory.
Bullish
- Deeply Discounted Valuation: SOLV trades at a trailing P/E of 8.87x and a forward P/E of 9.55x, which is a significant discount to typical healthcare supply peers and near the low end of its own volatile historical range. This low multiple suggests the market has priced in minimal growth, creating a margin of safety if the company can demonstrate any operational improvement.
- Strong Institutional Analyst Support: Despite limited coverage, the few analysts covering SOLV are predominantly bullish, with recent ratings including 'Overweight', 'Buy', and 'Outperform'. This institutional support provides a counter-narrative to the stock's technical weakness and suggests fundamental value is recognized by professional investors.
- Solid Profitability and Margins: The company maintains a robust gross margin of 49.3% (Q4 2025) and a trailing twelve-month operating margin of 26.2%. This underlying profitability, despite revenue headwinds, provides a financial cushion and demonstrates the business model's inherent strength in its core medical supply markets.
- Low Market Beta Reduces Downside Risk: With a beta of 0.774, SOLV is 22.6% less volatile than the broader market. This characteristic makes the stock a defensive holding, likely to decline less than the market in a downturn, which is attractive for risk-averse investors given its already depressed price level.
Bearish
- Persistent Revenue Decline and Stagnation: Q4 2025 revenue of $2.0B declined 3.71% YoY, continuing a two-year trend of stagnant to negative growth. The company's inability to grow its top line is the core bear argument, raising questions about its competitive position and long-term viability as a standalone entity.
- Pronounced Technical Downtrend: The stock is down 13.43% over 3 months and 15.68% YTD, significantly underperforming the SPY. It trades near its 52-week low of $62.38, with a negative relative strength of -6.44 over the past month, indicating a failure to participate in market rallies and persistent selling pressure.
- Negative Free Cash Flow and Capital Constraints: Trailing twelve-month free cash flow is negative $10 million, indicating the company is not generating surplus cash after capital expenditures. This limits its ability to invest in growth, pay down its debt-to-equity of 1.0, or return capital to shareholders without external financing.
- High Short Interest and Limited Liquidity: A short ratio of 4.49 indicates significant bearish speculative sentiment. Coupled with limited analyst coverage (only 3 firms), this can lead to exaggerated price moves and inefficient price discovery, increasing volatility and the risk of sharp declines on negative news.
SOLV Technical Analysis
The stock is in a pronounced downtrend, having declined 13.43% over the past three months and 15.68% year-to-date, significantly underperforming the broader market. With a current price of $66.63, the stock is trading near the lower end of its 52-week range, approximately 24.6% above its 52-week low of $62.38 and 24.5% below its 52-week high of $88.2, positioning it as a potential value opportunity but also indicating persistent selling pressure. Recent momentum shows a slight divergence, with a 3.54% gain over the past month, yet this positive move is weak relative to the SPY's 9.98% gain over the same period, as evidenced by a negative relative strength of -6.44, suggesting the stock is failing to participate in any broader market rally. Key technical support is clearly defined at the 52-week low of $62.38, while resistance sits near the 52-week high of $88.2; a sustained breakdown below $62.38 would signal a continuation of the bearish trend, whereas a recovery above the recent high near $86 from January would be needed to suggest a reversal. The stock's beta of 0.774 indicates it is 22.6% less volatile than the market, which, while reducing risk, also implies muted potential for outsized gains during market recoveries.
Beta
0.66
0.66x market volatility
Max Drawdown
-27.5%
Largest decline past year
52-Week Range
$62-$88
Price range past year
Annual Return
+0.4%
Cumulative gain past year
| Period | SOLV Return | S&P 500 |
|---|---|---|
| 1m | +14.2% | +8.6% |
| 3m | -7.8% | +6.7% |
| 6m | -0.2% | +9.8% |
| 1y | +0.4% | +26.6% |
| ytd | -5.0% | +8.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
SOLV Fundamental Analysis
Revenue growth is stagnant and recently turned negative, with Q4 2025 revenue of $1.998 billion representing a 3.71% year-over-year decline, continuing a trend of quarterly revenue hovering between $2.0 and $2.2 billion over the past two years. The company is profitable but with volatile margins; Q4 2025 net income was $63 million on a gross margin of 49.3%, but this follows an anomalous Q3 2025 where net income spiked to $1.266 billion due to a large non-operating gain, obscuring the underlying operating profitability which has been modest, with operating margins typically in the mid-single digits. The balance sheet shows moderate leverage with a debt-to-equity ratio of 1.0, and while the company generated positive operating cash flow of $95 million in Q4, its trailing twelve-month free cash flow is negative $10 million, indicating it is not currently generating surplus cash after capital expenditures to fund growth internally, though its current ratio of 1.23 suggests adequate short-term liquidity.
Quarterly Revenue
$2.0B
2025-12
Revenue YoY Growth
-0.03%
YoY Comparison
Gross Margin
+0.49%
Latest Quarter
Free Cash Flow
$-10000000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is SOLV Overvalued?
Given the company's positive net income, the primary valuation metric is the Price-to-Earnings (PE) ratio. The trailing PE is 8.87x, while the forward PE is 9.55x, a modest 7.7% premium that suggests the market anticipates only slight earnings growth in the near term. Compared to typical healthcare supplies peers, Solventum's trailing PE of 8.87x appears to be at a discount, though a precise industry average is not provided in the data; its Price-to-Sales ratio of 1.66x and EV/EBITDA of 7.04x provide additional context for its market valuation. Historically, the stock's own PE ratio has been highly volatile due to earnings fluctuations, but its current trailing multiple of 8.87x is near the lower end of its recent historical range, which has seen figures as high as 92.4x in Q4 2024 and as low as 2.5x in Q3 2025, suggesting the market is currently pricing in subdued expectations relative to its own erratic earnings history.
PE
8.9x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -11x~92x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
7.0x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are centered on stagnant growth and cash generation. Revenue declined 3.71% YoY in Q4 2025, and the company has not generated positive free cash flow over the past year (-$10M TTM), limiting internal investment capacity. While the debt-to-equity ratio of 1.0 is moderate, servicing this debt becomes challenging without revenue growth or consistent cash flow. Furthermore, earnings are highly volatile, as seen in the anomalous Q3 2025 net income spike, making underlying profitability difficult to assess and increasing earnings risk.
Market & Competitive Risks are elevated due to valuation compression and spin-off uncertainties. Trading at a significant discount to peers, the stock could face further multiple contraction if the market continues to penalize companies with no growth. As a recent spin-off, SOLV lacks an established track record as a standalone entity, increasing uncertainty and the risk of being overlooked by investors. Its low beta of 0.774, while defensive, also signals the market views it as a low-growth, low-expectation stock, making it vulnerable to sector rotations out of value and into growth.
The Worst-Case Scenario involves a failure of the standalone strategy, leading to a continued revenue slide and margin erosion. This could trigger analyst downgrades from the current bullish stance, accelerated selling from disappointed investors, and a test of the 52-week low. A specific chain of events could be: Q2 2026 earnings miss with another revenue decline, guidance lowered, leading to a breakdown of key technical support at $62.38. From the current price of $66.63, a realistic downside in this adverse scenario is a decline of approximately -20% to retest the $53-$55 range, extrapolating from the stock's maximum drawdown of -27.46% observed in the provided data.
FAQ
The key risks are, in order of severity: 1) Operational Risk: Continued revenue decline, as seen in the -3.71% YoY drop in Q4 2025, which threatens the core business thesis. 2) Financial Risk: Inability to generate consistent positive free cash flow (TTM -$10M), limiting strategic options. 3) Market/Sentiment Risk: High short interest (short ratio 4.49) and persistent technical downtrend (-13.43% over 3 months) can lead to exaggerated selling pressure. 4) Company-Specific Risk: Execution challenges as a newly independent spin-off with limited analyst coverage, increasing uncertainty and volatility.
The 12-month forecast is highly uncertain, centered on three scenarios. The Base Case (60% probability) sees the stock trading sideways in a $70-$78 range, as stagnant fundamentals keep it range-bound. The Bull Case (25% probability), fueled by a revenue turnaround, targets $85-$92. The Bear Case (15% probability), involving accelerating declines, sees a drop to $55-$62. The base case is most likely, predicated on the assumption that revenue remains flat and the company fails to provide a clear growth catalyst, leaving the stock stuck in a value trap. The wide analyst EPS range ($7.26-$8.00) underscores this uncertainty.
SOLV appears significantly undervalued based on traditional earnings multiples. Its trailing P/E of 8.87x and forward P/E of 9.55x are at a steep discount to the broader healthcare sector. Its Price-to-Sales ratio of 1.66x is also modest. However, this valuation likely reflects the market's justified concerns over its -3.71% YoY revenue decline and negative free cash flow. The stock is fairly valued or slightly undervalued relative to its current challenged fundamentals, but the discount is not deep enough to be compelling without evidence of a fundamental turnaround. The market is pricing in stagnation.
SOLV is a high-risk, high-potential-reward stock that may be a good buy only for a specific type of investor. For deep-value, contrarian investors willing to accept the risk of further decline, the current P/E of 8.87x offers a significant margin of safety. The ~25% implied upside to the analyst consensus (based on EPS estimates) is attractive. However, the key downside risk is continued revenue erosion, which could lead to multiple compression. It is not a good buy for growth investors or those with a short time horizon, as a catalyst for re-rating may take multiple quarters to materialize, if at all.
SOLV is strictly a long-term investment, with a suggested minimum holding period of 2-3 years. The stock's low beta (0.774) and lack of a dividend make it unattractive for short-term trading, as it lacks volatility-driven opportunities and income. The investment thesis is based on a potential multi-year turnaround story post-spin-off, which requires time to unfold. Short-term price action is likely to be dominated by technical factors and sentiment, while the fundamental value realization that bulls anticipate is a long-term process. It is suitable only for patient capital in a diversified portfolio.